Cite
Rituximab monotherapy in splenic marginal zone lymphoma: prolonged responses and potential benefit from maintenance
MLA
Maria N. Dimopoulou, et al. “Rituximab Monotherapy in Splenic Marginal Zone Lymphoma: Prolonged Responses and Potential Benefit from Maintenance.” Blood, vol. 132, Aug. 2018, pp. 666–70. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....9c3d1c1464258ae797dd8c7d0a8ec1ca&authtype=sso&custid=ns315887.
APA
Maria N. Dimopoulou, Flora N. Kontopidou, Eleni Plata, Efstathios Koulieris, Panagiotis Panagiotidis, Gerassimos A. Pangalis, Maria K. Angelopoulou, Pantelis Tsirkinidis, Xanthi Yiakoumis, Maria Moschogiannis, Dimitra Rontogianni, Penelope Korkolopoulou, Sotirios Sachanas, Panagiotis Tsaftaridis, Christina Kalpadakis, Gerassimos Tsourouflis, Helen A. Papadaki, Marina P. Siakantaris, Theodoros P. Vassilakopoulos, … Stella I. Kokkoris. (2018). Rituximab monotherapy in splenic marginal zone lymphoma: prolonged responses and potential benefit from maintenance. Blood, 132, 666–670.
Chicago
Maria N. Dimopoulou, Flora N. Kontopidou, Eleni Plata, Efstathios Koulieris, Panagiotis Panagiotidis, Gerassimos A. Pangalis, Maria K. Angelopoulou, et al. 2018. “Rituximab Monotherapy in Splenic Marginal Zone Lymphoma: Prolonged Responses and Potential Benefit from Maintenance.” Blood 132 (August): 666–70. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....9c3d1c1464258ae797dd8c7d0a8ec1ca&authtype=sso&custid=ns315887.